COMPAZINE
LOE ApproachingNDARECTALSUPPOSITORY
Approved
Jan 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is a phenothiazine antipsychotic approved as a rectal suppository since 1959. The exact current indications are not specified in available data, but phenothiazines have historically been used for psychosis, nausea/vomiting, and anxiety. This small-molecule drug works by antagonizing dopamine and other neurotransmitter receptors in the central nervous system.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on cost management and niche positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers minimal career growth potential given its LOE-approaching status and zero linked job openings. Career moves here are typically stabilization or wind-down roles focused on protecting remaining market share and optimizing profitability.
Brand ManagerCommercial Operations Manager
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.